Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 5 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 5 of 10.)

DateHeadlineEventSource5-minTo close
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary diseasePress releasePR Newswire-0.38%-0.77%
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphomaPress releasePR Newswire+0.10%-0.09%
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemiaPress releasePR Newswire+0.07%+0.41%
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritisPress releasePR Newswire+0.01%-0.67%
Form 8-K JOHNSON & JOHNSON For: Jun 10SEC filing · Form 8-KSEC EDGAR+0.01%-0.67%
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of DirectorsPress releaseBusiness Wire+0.01%-0.67%
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativityPress releasePR Newswire-0.06%-0.28%
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patientsPress releasePR Newswire-0.08%-0.30%
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPCPress releasePR Newswire+0.12%-0.24%
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myelomaPress releasePR Newswire-0.07%-0.29%
Form SD JOHNSON & JOHNSONSEC filing · Form SDSEC EDGAR+0.63%+1.21%
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsPress releaseBusiness Wire+0.63%+1.21%
Products That Count Announces Winners of the 2025 Q1 Product Manager AwardsPress releasePR Web-0.03%-0.27%
Jessica Dean Named to National Law Journal’s 2025 Elite Women of the Plaintiffs BarPress releaseBusiness Wire-0.06%+0.32%
FDA Panel Reiterates the Cancer Risks of TalcPress releaseBusiness Wire-0.15%-0.04%
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions ConferencePress releaseBusiness Wire+0.09%-0.06%
Dean Omar Branham Shirley Recognized Twice Among ALM’s 2024 Top 100 VerdictsPress releaseBusiness Wire+0.06%+0.33%
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myelomaPress releasePR Newswire+0.27%-0.01%
Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology UnitPress releaseBusiness Wire+0.22%+0.40%
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy FailsPress releaseBusiness Wire-0.17%+1.11%
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferencePress releaseBusiness Wire+0.09%+0.88%
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasisPress releasePR Newswire-0.01%-0.77%
Johnson & Johnson expands efforts to champion the nursing workforce globallyPress releaseBusiness Wire+0.25%-0.10%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR+0.25%-0.10%
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two yearsPress releasePR Newswire-0.84%-1.07%
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeksPress releasePR Newswire-0.84%-1.07%
Form 8-K JOHNSON & JOHNSON For: Apr 24SEC filing · Form 8-KSEC EDGAR-0.69%-0.35%
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)Press releasePR Newswire-0.93%-1.07%
Products That Count Announces Winners of the 2025 Q1 Product AwardsPress releasePR Web-0.04%+0.42%
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions ConferencePress releaseBusiness Wire-0.19%+0.30%
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBCPress releasePR Newswire-0.33%-0.10%
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancerPress releasePR Newswire-0.33%-0.10%
Roswell Park Expert to Share Promising Results on New Immunotherapy Approach in Non-Small Cell Lung CancerPress releasePR Web-0.33%-0.10%
Form 10-Q JOHNSON & JOHNSON For: Mar 30SEC filing · Form 10-QSEC EDGAR-0.91%-0.56%
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUAPress releasePR Newswire-0.26%-0.69%
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025Press releasePR Web-0.25%-0.66%
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire+1.46%+2.15%
Form 8-K JOHNSON & JOHNSON For: Apr 15SEC filing · Form 8-KSEC EDGAR-0.82%-1.72%
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%Press releaseBusiness Wire-0.82%-1.72%
Johnson & Johnson Reports Q1 2025 ResultsPress releaseBusiness Wire-0.82%-1.72%
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pillPress releasePR Newswire-0.69%-1.12%
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)Press releasePR Newswire-1.08%-2.28%
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare ConferencePress releaseBusiness Wire-1.08%-2.28%
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritisPress releasePR Newswire-0.39%-3.97%
Form 8-K JOHNSON & JOHNSON For: Mar 31SEC filing · Form 8-KSEC EDGAR-0.39%-3.97%
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience LeadershipPress releaseBusiness Wire+0.11%+0.69%
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial CourtsPress releaseBusiness Wire-1.05%-5.16%
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular AcquisitionPress releaseBusiness Wire+0.11%+0.69%
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc ClaimsPress releaseBusiness Wire-1.05%-5.16%
Med One Announces the Hiring of Sheri Thomas as Chief Financial OfficerPress releasePR Web+0.14%+0.15%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground